Modern approaches to the therapy of invasive mycoses in cancer patients

封面

如何引用文章

全文:

详细

There is an increase in the prevalence of Candida fluco-R, there is a transition from strains of C. albicans to C. non-albicans. Diagnosis of invasive fungal infections is based on a clinical picture and risk factor assessment with subsequent retrospective confirmation of the diagnosis by a microbiological method. Echinocandines are the drugs of choice in the therapy of invasive/systemic mycoses in cancer patients.

作者简介

Aleksey Prikhodchenko

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

编辑信件的主要联系方式.
Email: evpatii2004@mail.ru
ORCID iD: 0000-0002-4770-0034

Cand. Sci. (Med.)

俄罗斯联邦, Moscow

Valentina Nechuskina

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: evpatii2004@mail.ru
ORCID iD: 0000-0002-1855-9692

D. Sci. (Med.)

俄罗斯联邦, Moscow

Pavel Vyatkin

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: evpatii2004@mail.ru
ORCID iD: 0000-0003-2976-2562

anesthesiologist-resuscitator

俄罗斯联邦, Moscow

参考

  1. Веселов А.В. Эмпирическая терапия инвазивного кандидоза в отделениях реанимации и интенсивной терапии: современное состояние проблемы. Клиническая микробиология и антимикробная химиотерапия. 2011;13(1):4-18 [Veselov AV. Empiricheskaia terapiia invazivnogo kandidoza v otdeleniiakh reanimatsii i intensivnoi terapii: sovremennoe sostoianie problemy. Klinicheskaia mikrobiologiia i antimikrobnaia khimioterapiia. 2011;13(1):4-18 (in Russian)].
  2. Нехаев И.В., Приходченко А.О., Ломидзе С.В., Сытов А.В. Интенсивная терапия системных микозов в онкохирургии. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2014;25(1–2):52-8 [Nekhaev IV, Prikhodchenko AO, Lomidze SV, Sytov AV. Intensivnaia terapiia sistemnykh mikozov v onkokhirurgii. Vestnik RONTs im. N.N. Blokhina RAMN. 2014;25(1–2):52-8 (in Russian)].
  3. Нехаев И.В., Приходченко А.О., Ломидзе С.В., Сытов А.В. Диагностика и лечение системных микозов в онкохирургии. Инфекции в хирургии. 2014;2:17-21 [Nekhaev IV, Prikhodchenko AO, Lomidze SV, Sytov AV. Diagnostika i lechenie sistemnykh mikozov v onkokhirurgii. Infektsii v khirurgii. 2014;2:17-21 (in Russian)].
  4. Нехаев И.В., Приходченко А.О., Бударгин Е.Е., и др. Флуконазол. Эхинокандины. Системные микозы. Медицинский алфавит. 2015;3(14):23-9 [Nekhaev IV, Prikhodchenko AO, Budargin EE, et al. Flukonazol. Ekhinokandiny. Sistemnye mikozy. Meditsinskii alfavit. 2015;3(14):23-9 (in Russian)].
  5. Wey SB, Mori M, Pfaller MA, et al. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med. 1988;148:2642-5.
  6. Voss A, le Noble JL, Verduyn Lunel FM, et al. Candidemia in intensive care unit patients: risk factors for mortality. Infection. 1997;25:8-11.
  7. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med. 2002;113:480-5.
  8. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-17.
  9. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37:1172-7.
  10. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232-9.
  11. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640-5.
  12. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25-31.
  13. Vincent JL, Rello J, Marshall J, et al. EPIC II Group of Investigators: International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323-9.
  14. Engel C, Brunkhorst FM, Bone HG, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007;33:606-18.
  15. Tortorano AM, Kibbler C, Peman J, et al. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents. 2006;27:359-66.
  16. Guery BP, Arendrup MC, Auzinger G, et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med. 2009;35:55-62.
  17. Muñoz P, Burillo A, Bouza E. Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. Int J Antimicrob Agents. 2000;15:83-90.
  18. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am. 2003;17:113-34.
  19. Pelz RK, Lipsett PA, Swoboda SM, et al. The diagnostic value of fungal surveillance cultures in critically ill patients. Surg Infect (Larchmt). 2000;1:273-81.
  20. Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362:1142-51.
  21. Pound MW, Townsend ML, Drew RH. Echinocandin pharmacodynamics: review and clinical implications. J Antimicrob Chemother. 2010;65(6):1108-18.
  22. Pfaller MA, Boyken L, Hollis RJ, et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol. 2010;48(1):52-6.
  23. Kale-Pradhan PB, Morgan G, Wilhelm SM, Johnson LB. Comparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsilosis Infections: a meta-analysis. Pharmacotherapy. 2010;30:1207-13.
  24. Sun HY, Singh N. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int J Antimicrob Agents. 2010;35:211-18.
  25. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat. 2007;10:121-30.
  26. Cota J, Carden M, Graybill JR, et al. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemother. 2006;50(11):3926-8.
  27. Edlind T, Healey K, Jphnson M, Katiyar S. Candida glabrata CRS-MIS Mutants: Caspofungin Reduced Susceptibility but Micafungin Increased Susceptibility. 2010. Poster M-393; 50th ICAAC, Boston, MA, USA.
  28. Niwa T, Yokota Y, Tokunaga A, et al. Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats. Biol Pharm Bull. 2004;27:1154-6.
  29. Hajdu R, Thompson R, Sundelof JG, et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743, 872). Antimicrob Agents Chemother. 1997;41:2339-44.
  30. Damle B, Stogniew M, Dowell J. Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob Agents Chemother. 2008;52:2673-6.
  31. Damle BD, Dowell JA, Walsky RL, et al. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob Agents Chemother. 2009;53:1149-56.
  32. Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag. 2007;3:71-97.
  33. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis. 2003;36:1445-57.
  34. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis. 2006;42:1171-8.
  35. Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis. 2006;43:215-22.
  36. Krause DS, Reinhardt J, Vazquez JA, et al. Anidulafungin Invasive Candidiasis Study Group. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother. 2004;48:2021-4.
  37. Dowell JA, Knebel W, Ludden T, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol. 2004;44:590-8.
  38. Dowell JA, Stogniew M, Krause D, Damle B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol. 2007;47:461-70.
  39. European Medicines Agency. Ecalta® summary of product characteristics. 2010.
  40. Dowell JA, Stogniew M, Krause D, et al. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol. 2005;45:227-33.
  41. Dowell JA, Stogniew M, Krause D, et al. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol. 2007;47:305-14.
  42. Dowell JA, Schranz J, Baruch A, Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol. 2005;45:1373-82.
  43. Stone JA, Migoya EM, Hickey L, et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother. 2004;48:4306-14.
  44. Betts RF, Nucci M, Talwar D, et al. Caspofungin High-Dose Study Group A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis. 2009;48:1676-84.
  45. Mistry GC, Migoya E, Deutsch PJ, et al. Single-and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations. J Clin Pharmacol. 2007;47:951-61.
  46. European Medicines Agency. Cancidas® summary of product characteristics. 2009. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/cancidas-previously-caspofungin-msd. Accessed: 24.08.2020.
  47. European Medicines Agency. Mycamine® summary of product characteristics. 2010. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/mycamine. Accessed: 25.08.2020.
  48. Sandven P, Bevanger L, Digranes A, et al. Norwegian Yeast Study Group Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol. 2006;44:1977-81.
  49. Slavin MA, Sorrell TC, Marriott D, et al. Australian Candidemia Study, Australasian Society for Infectious Diseases: Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother. 2010;65:1042-51.
  50. Kumar A, Skrobik I, Guzman J, et al. CATSS Database Research Group. The high mortality of Candida septic shock is explained by excessive delays in initiation of antifungal therapy. Poster K-2174; 47th ICAAC, Chicago, IL, USA, 2007.
  51. Taur Y, Cohen N, Dubnow S, et al. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother. 2010;54:184-90.
  52. European Medicines Agency. Diflucan® summary of product characteristics. 2010. Available at: https://www.ema.europa.eu/en/medicines/human/referrals/diflucan. Accessed: 24.08.2020.
  53. Nivoix Y, Ubeaud-Sequier G, Engel P, et al. Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr Drug Metab. 2009;10(4):395-409.
  54. Kullberg BJ, Vasquez J, Mootsikapun P. Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials. J Antimicrob Chemother. 2017;72(8):2368-77. doi: 10.1093/jac/dkx116

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Dependence of the mortality rate (%) on the time of initiation of antifungal therapy [11].

下载 (42KB)
索引源数据

版权所有 © Consilium Medicum, 2021

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##